244 related articles for article (PubMed ID: 15377314)
21. Botulinum toxin in migraine prophylaxis.
Göbel H
J Neurol; 2004 Feb; 251 Suppl 1():I8-11. PubMed ID: 14991336
[TBL] [Abstract][Full Text] [Related]
22. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial.
Vo AH; Satori R; Jabbari B; Green J; Killgore WD; Labutta R; Campbell WW
Aviat Space Environ Med; 2007 May; 78(5 Suppl):B113-8. PubMed ID: 17547312
[TBL] [Abstract][Full Text] [Related]
23. Duration of migraine is a predictor for response to botulinum toxin type A.
Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW
Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
[TBL] [Abstract][Full Text] [Related]
24. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
Lowe NJ; Glaser DA; Eadie N; Daggett S; Kowalski JW; Lai PY;
J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
[TBL] [Abstract][Full Text] [Related]
25. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial.
Singh JA; Mahowald ML; Noorbaloochi S
Transl Res; 2009 May; 153(5):205-16. PubMed ID: 19375681
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum toxin for migraine.
Schwedt TJ; Hentz JG; Dodick DW
Cephalalgia; 2007 Jun; 27(6):528-34. PubMed ID: 17459081
[TBL] [Abstract][Full Text] [Related]
27. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.
Monheit G; Carruthers A; Brandt F; Rand R
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S51-9. PubMed ID: 17241415
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M
Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050
[TBL] [Abstract][Full Text] [Related]
29. Botulinum toxin A for the treatment of delayed gastric emptying.
Friedenberg FK; Palit A; Parkman HP; Hanlon A; Nelson DB
Am J Gastroenterol; 2008 Feb; 103(2):416-23. PubMed ID: 18070232
[TBL] [Abstract][Full Text] [Related]
30. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders.
Dodick D; Blumenfeld A; Silberstein SD
Clin Dermatol; 2004; 22(1):76-81. PubMed ID: 15158549
[TBL] [Abstract][Full Text] [Related]
31. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults.
Wendt J; Cady R; Singer R; Peters K; Webster C; Kori S; Byrd S
Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463
[TBL] [Abstract][Full Text] [Related]
32. Role of botulinum toxin type A in the prophylactic treatment of migraine headaches.
Chilson CN; Brown SJ
Ann Pharmacother; 2005 Dec; 39(12):2081-5. PubMed ID: 16264063
[TBL] [Abstract][Full Text] [Related]
33. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis.
Elkind AH; O'Carroll P; Blumenfeld A; DeGryse R; Dimitrova R;
J Pain; 2006 Oct; 7(10):688-96. PubMed ID: 17018329
[TBL] [Abstract][Full Text] [Related]
34. Botulinum toxin type A for migraine. First, do no harm.
Prescrire Int; 2011 Dec; 20(122):287-90. PubMed ID: 22216539
[TBL] [Abstract][Full Text] [Related]
35. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
36. Valdecoxib for treatment of a single, acute, moderate to severe migraine headache.
Kudrow D; Thomas HM; Ruoff G; Ishkanian G; Sands G; Le VH; Brown MT
Headache; 2005 Oct; 45(9):1151-62. PubMed ID: 16178945
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
[TBL] [Abstract][Full Text] [Related]
38. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.
Goadsby PJ; Ferrari MD; Csanyi A; Olesen J; Mills JG;
Cephalalgia; 2009 Jul; 29(7):742-50. PubMed ID: 19222510
[TBL] [Abstract][Full Text] [Related]
39. A prospective randomized controlled study of the role of botulinum toxin in whiplash-associated disorder.
Carroll A; Barnes M; Comiskey C
Clin Rehabil; 2008 Jun; 22(6):513-9. PubMed ID: 18511531
[TBL] [Abstract][Full Text] [Related]
40. Botulinum toxin type A (BOTOX) for treatment of migraine.
Binder WJ; Brin MF; Blitzer A; Pogoda JM
Semin Cutan Med Surg; 2001 Jun; 20(2):93-100. PubMed ID: 11474749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
